CHOOSE
Find the peptide category aligned with the specific research goal.
FREE SHIPPING OVER €100
•
THIRD-PARTY LAB TESTED
•
SHIPS FROM UNITED STATES
•
A practical learning center for understanding veterinary recovery peptides, species considerations, measurement, protocols and responsible research use.
Information provided is for educational and research purposes. Always seek direct guidance from a licensed veterinarian.
Find the peptide category aligned with the specific research goal.
Understand species, weight and concentration variables.
Learn reconstitution, storage and preparation basics.
Understand cycling, protocols and responsible research use.
Targeted support for soft-tissue recovery and connective tissue.
RELEVANT PEPTIDESStudied for gastric support and intestinal lining integrity.
RELEVANT PEPTIDESResearch focused on immune modulation and cellular defense.
RELEVANT PEPTIDESInvestigated for surface healing and dermatological support.
RELEVANT PEPTIDESStudied in models of muscle atrophy and metabolic recovery.
RELEVANT PEPTIDESAdvanced protocols requiring direct veterinary oversight.
RELEVANT PEPTIDESProtocols vary significantly between dogs, cats, and horses due to metabolic differences and body mass. Select a species to review relevant peptide applications.
Dogs tolerate these peptides well across a broad weight range. Scale the dose to body weight, place injections near the injury where the protocol allows, and rotate sites to keep tissue comfortable.
A versatile research option for gut issues, tendon and ligament strain, and recovery after surgery. It is studied for supporting early healing signals involved in tissue repair.
Size-based ranges should be followed carefully and injection sites monitored throughout the research period.
Studied for structural recovery involving tendon, ligament, muscle and persistent wounds. It is often researched alongside BPC-157 when complementary recovery pathways are being considered.
Research guidance on the existing Academy page advises avoiding TB-500 in animals with active cancer and checking competition rules where relevant.
Studied as an immune-modulating peptide in canine research involving chronic or recurring infection and immune-response support.
The Academy describes it as generally well tolerated, with standard clean technique and veterinary oversight recommended.
Researched for wounds, skin and coat quality and joint comfort. Topical application may be used when the research target is localised.
Extra care is advised for breeds prone to copper-storage disease, with liver monitoring relevant when injectable forms are being studied.
Studied for muscle wasting and rebuilding strength after surgery where a stronger growth-related research signal is being investigated.
The Academy specifies mandatory cycling and advises against use where active cancer is present. Blood glucose monitoring is also noted.
An investigational research peptide studied in relation to HDM-2-expressing tumours.
The Academy identifies this as veterinary-supervised research that should sit alongside, rather than replace, an established veterinary cancer plan.
Studied as a localised muscle-repair signal, with administration research focused near the site requiring recovery.
The Academy advises against combining MGF with IGF-1 LR3 because of overlapping pathways and notes avoidance where active cancer is present.
Cats need a gentler hand: per-kilogram doses run lower, injection volumes are tiny, and a baseline liver panel is worth having before copper-based peptides. Cats can react to repeated injections in the same spot, so rotate sites every time and have a veterinarian check any persistent lump.
Studied as a conservative research option for gastrointestinal issues, soft-tissue healing and post-surgical recovery in cats.
Feline injection volumes are very small, making accurate measurement and conservative research protocols particularly important.
Studied for tendon, ligament and wound-repair research in cats using a short loading phase followed by maintenance.
The Academy specifically advises lateral-trunk injection rather than the interscapular region and notes avoidance in cats with active tumours.
Investigated for immune support in cats, including research relating to chronic viral conditions and immune modulation.
Existing Academy guidance describes it as generally well tolerated with standard clean technique and veterinary oversight.
Studied for wound, skin and coat support in cats, with topical research particularly relevant to localised surface applications.
Because cats are copper-sensitive, the Academy recommends caution, baseline liver assessment and avoiding GHK-Cu in cats with liver disease or cancer.
Researched as a short, cycled approach to muscle recovery in cats where growth-factor research is relevant.
Feline data is limited. The Academy notes contraindications including feline acromegaly and active cancer and stresses appropriate cycling.
An investigational tumour-targeting research option in feline models, with intratumoral research discussed where a lesion is accessible.
The Academy restricts this information to veterinary-supervised research alongside an established cancer-care plan.
Studied for targeted muscle-repair research in cats using a relatively short research period.
Existing guidance advises against combining MGF with IGF-1 LR3 because their growth-factor signals overlap.
Horse doses scale by body surface area rather than straight weight, so totals may appear larger while per-kilogram exposure remains modest. For competition horses, detection windows and withdrawal requirements should also be considered.
Studied in equine research involving tendon and ligament strain as well as gastrointestinal applications.
Competition-testing considerations and appropriate withdrawal windows should be reviewed where applicable.
Investigated for deeper tendon, ligament and muscle recovery in horses, using a loading phase followed by longer maintenance research.
Existing Academy guidance highlights racing restrictions, withdrawal considerations and avoidance in horses with active cancer.
Studied for immune support in horses, including investigational interest in immune resilience and selected equine conditions.
The Academy describes the peptide as generally well-tolerated when researched under veterinary oversight.
Studied for wound and hoof-care research in horses where copper-dependent collagen and tissue-repair pathways are relevant.
Injectable research may warrant liver monitoring, while topical research is discussed separately in the existing Academy guidance.
Studied as a localised growth-related signal in equine muscle and soft-tissue recovery research.
Existing guidance requires cycling, notes tumour-related contraindications and identifies blood-glucose and competition considerations.
Investigational equine research has examined PNC-27 in relation to conditions including sarcoid, melanoma and squamous-cell carcinoma.
The Academy characterises this as early-stage research requiring close veterinary supervision.
Studied for targeted recovery at the equine muscle-tendon junction where localised loading and repair pathways are of research interest.
The Academy advises against stacking with IGF-1 LR3 and notes competition clearance considerations.
Select Dog Weight
4.5 kg
Once daily, subcutaneous. Cycle 2–4 weeks for active injuries; extend or repeat for chronic conditions.
Subcutaneous. Loading 2× weekly for 4–6 weeks, then maintenance every 7–14 days.
These values reproduce the supplied Academy reference content. Both peptides are described there as subcutaneous and off-label. Treat every figure as a reference point to confirm with a qualified veterinarian.
Run a peptide non-stop and the body adapts — receptors quietly downregulate and the same dose starts doing less. A scheduled break lets those receptors recover, so the next block lands with its full effect instead of a fading one.
A short rest week between blocks keeps it working; for an acute injury it can run continuously for up to four weeks.
Front-load to build it up, hold a longer maintenance phase, then break for four weeks before loading again.
A long on-phase then a short break — but for active cancer, FIV or FeLV your vet may keep it running continuously.
Injectable courses cycle on and off; the topical form is gentler and can be applied continuously.
Cycling is not optional: four weeks on, four weeks off, and no more than three cycles in total.
Same strict four-on / four-off schedule, capped at three cycles — and never stacked with IGF-1 LR3.
Pairing complementary peptides covers more of the healing arc than any single one can. Here are the two recovery protocols we reach for most — plus an honest note on the investigational combinations that sit outside everyday practice.
BPC-157 + TB-500
The most thoroughly documented synergistic combination in veterinary research. BPC-157 provides localized anti-inflammatory and cellular repair signaling, while TB-500 offers systemic actin-binding properties to support broad tissue remodeling.
GHK-Cu + BPC-157 + TB-500
A highly advanced research protocol focusing on surface recovery, dermatological health, and scar mitigation. GHK-Cu is introduced specifically for its established role in collagen synthesis and copper delivery to damaged tissues.
Combinations involving PNC-27 or specialized immune-modulating peptides require explicit, direct veterinary oncology supervision. These are strictly investigational.
Clean the vial stopper with alcohol.
Part the fur and clean the skin (if protocol dictates).
Use a fresh, sterile syringe every single time.
NEVER mix multiple peptides in the same syringe.
Inject swiftly and smoothly to minimize discomfort.
Dispose of syringes in a proper sharps container.
Every species has its own map of safe spots. Use the diagrams to picture each location, then work from the numbered list — that list is the source of truth. Rotate sites every dose and keep a written record of where each one went.
Diagram is illustrative — marker positions are approximate. Follow the numbered list and your vet’s guidance.
The everyday subcutaneous spot. Tent the loose skin between the shoulder blades, slide the needle in at about 45°. Reach for a 25–27G and keep each dose to roughly 0.5–1 mL.
Plenty of give in the skin along the ribcage makes this a great daily-rotation site. Alternate left and right so the same patch never takes two doses running.
The fold ahead of the hind leg offers the most spare skin, so it suits slightly larger volumes. Swap sides each time to spread the load.
The go-to intramuscular site. Go in perpendicular with a 22–25G and always draw back on the plunger first — if you see blood, pull out and pick a fresh spot.
The muscle running either side of the spine takes a localised IM dose. Stay to the side of the backbone, never over it.
Diagram is illustrative — marker positions are approximate. Follow the numbered list and your vet’s guidance.
The site to reach for first. Injecting along the side of the body rather than the scruff lowers FISS risk. Rotate every dose and use a fine 25–27G.
Pair this with the left flank and alternate between them. Keep the angle shallow — around 30–45° into the tented skin.
Swap with the right chest on a rotation. Cats take small volumes well, so keep each dose under 0.5 mL.
Usually the only intramuscular site you will need in a cat. Use a 25G, keep the dose under 0.3 mL, and aspirate before you push.
Repeated jabs between the shoulder blades are linked to feline injection-site sarcoma (FISS), so use the lateral body-wall sites, rotate every dose, and note where each one went. It is easy to do well — and worth having your vet check any lump that lasts more than a month, grows, or is bigger than a pea.
Diagram is illustrative — marker positions are approximate. Follow the numbered list and your vet’s guidance.
The main IM site. Aim for the triangle that sits below the nuchal ligament, above the cervical vertebrae and in front of the shoulder blade. An 18–20G × 1.5 in takes up to 20 mL.
For shallow, systemic doses, tent the neck skin and inject just under the surface with a 20–22G. Rotate left and right between sessions.
A useful secondary IM site, handy when you are targeting the front limbs. Go in perpendicular to the muscle.
A big muscle that takes higher-volume IM doses comfortably. Keep clear of the sciatic nerve toward the back of the leg.
For tendon or ligament work, place the IM dose as close to the injury as is practical. This one is best left to your vet.
Peptide vial, bacteriostatic (BAC) water, alcohol swabs, and mixing syringe.
Pop caps off peptide and BAC water. Swab both rubber stoppers with alcohol.
Pull the mathematically correct volume of BAC water into the mixing syringe.
Inject water SLOWLY down the side of the peptide glass. Do not blast the powder.
Roll the vial gently between your fingers. NEVER SHAKE.
Write the reconstitution date and concentration on the vial. Refrigerate immediately.
| VIAL SIZE | BAC WATER ADDED | CONCENTRATION | PER 10 UNITS (0.1ML) |
|---|---|---|---|
| 10 mg | 2 ml | 5 mg / ml | 500 mcg |
| 10 mg | 3 ml | 3.33 mg / ml | 333 mcg |
| 5 mg | 2 ml | 2.5 mg / ml | 250 mcg |
Share your pet’s age, weight and specific recovery situation with our team and explore the available guidance and resources. No pressure. Just clearer information.
